Meir J. Stampfer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Meir J. Stampfer has a total of 406 co-authors. Here are the top co-authors by number of shared publications:
- Edward L. Giovannucci
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
36 shared publications - Jean Wactawski-Wende
Department of Epidemiology and Environmental Health, University at Buffalo , Buffalo, NY
31 shared publications - Fred K. Tabung
The Ohio State University
27 shared publications - JoAnn E. Manson
Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
27 shared publications - Peter Kraft
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health , Rockville, MD
27 shared publications - Julie E. Buring
Brigham and Women’s Hospital, Harvard Medical School
26 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S1 shows assessment of oral health variables across studies
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S1 shows assessment of oral health variables across studies
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S3 the multivariable hazard ratios and 95% confidence intervals for the association between oral health indicators and risk of liver cancer in the HPFU, NHS and WHI cohorts by smoking status
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S3 the multivariable hazard ratios and 95% confidence intervals for the association between oral health indicators and risk of liver cancer in the HPFU, NHS and WHI cohorts by smoking status
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S2 shows the search terms used for the meta-analyses
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S2 shows the search terms used for the meta-analyses
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S4 shows the sensitivity analysis for the meta-analysis of periodontal disease and number of missing teeth with liver cancer risk
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S4 shows the sensitivity analysis for the meta-analysis of periodontal disease and number of missing teeth with liver cancer risk
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S5 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S5 shows the sensitivity analysis of the effect of omitting one study at a time from the meta-analysis
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S5 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Supplemental Table S5 shows the sensitivity analysis of the effect of omitting one study at a time from the meta-analysis
- Open Access
- 20 August 2026
- Published by Elsevier in Journal of the Academy of Nutrition and Dietetics
- Vol. 127 (1)
Life Course Dietary Insulinemic and Inflammatory Potential and Risk of Type 2 Diabetes in United States Women: A Prospective Cohort Study
- 20 August 2026
- Published by Elsevier in Journal of the Academy of Nutrition and Dietetics
- Vol. 127 (1)
Open AccessLife Course Dietary Insulinemic and Inflammatory Potential and Risk of Type 2 Diabetes in United States Women: A Prospective Cohort Study
- Open Access
- 14 August 2026
- Published by Elsevier in SSRN Electronic Journal
Plasma Metabolomic Signature of the Planetary Health Diet and Risk of Cardiovascular Disease and Mortality: A Prospective Cohort Study
Background: The Planetary Health Diet Index (PHDI) quantifies adherence to the planetary health diet, aiming to promote human health and environmental sustainability. While self-reported PHDI is linked to lower cardiometabolic risk, the underlying biological pathways remain unclear. We aimed to identify a metabolomic signature of PHDI and evaluate its association with cardiovascular disease (CVD) and mortality.Methods: In this prospective cohort study, we included 11,190 adults from three US cohorts (Nurses’ Health Study [NHS], NHS II, and Health Professionals Follow-up Study) with up to 30 years of follow-up. Self-reported PHDI and covariates, including body-mass index (BMI), sociodemographic, and lifestyle factors, were derived from the two questionnaires closest to blood draw. Plasma metabolites were profiled using liquid chromatography-tandem mass spectrometry. We used elastic net regression to identify a metabolomic signature of the PHDI. Associations with incident CVD (1,861 events) and mortality (3,788 deaths) were assessed using Cox proportional hazards models. Findings were replicated in the Women’s Health Initiative (WHI; n=1,711).Findings: We identified an 84-metabolite signature of PHDI (Pearson r=0·46), characterised by higher long-chain highly unsaturated lipids and plant-related amino acids and lower carnitines and saturated lipid species, reflecting favourable lipid remodelling and oxidative stress modulation. Higher metabolomic PHDI was associated with lower risks of CVD (hazard ratio [HR] per 1-SD increment 0·95 [95% CI 0·90-1·00]) and total mortality (0·93 [0·89-0·96]), independently of self-reported PHDI, BMI, and other conventional risk factors. The signature was replicated in WHI for CVD (0·92 [0·84-1·00]).Interpretation: We identified and validated a metabolomic signature of PHDI that captures biological pathways linking adherence to a sustainable dietary pattern with cardiovascular health. These findings provide mechanistic insight into the potential cardiometabolic benefits of the planetary health diet and identify metabolic pathways that could inform future prevention strategies.
- 14 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPlasma Metabolomic Signature of the Planetary Health Diet and Risk of Cardiovascular Disease and Mortality: A Prospective Cohort Study
Background: The Planetary Health Diet Index (PHDI) quantifies adherence to the planetary health diet, aiming to promote human health and environmental sustainability. While self-reported PHDI is linked to lower cardiometabolic risk, the underlying biological pathways remain unclear. We aimed to identify a metabolomic signature of PHDI and evaluate its association with cardiovascular disease (CVD) and mortality.Methods: In this prospective cohort study, we included 11,190 adults from three US cohorts (Nurses’ Health Study [NHS], NHS II, and Health Professionals Follow-up Study) with up to 30 years of follow-up. Self-reported PHDI and covariates, including body-mass index (BMI), sociodemographic, and lifestyle factors, were derived from the two questionnaires closest to blood draw. Plasma metabolites were profiled using liquid chromatography-tandem mass spectrometry. We used elastic net regression to identify a metabolomic signature of the PHDI. Associations with incident CVD (1,861 events) and mortality (3,788 deaths) were assessed using Cox proportional hazards models. Findings were replicated in the Women’s Health Initiative (WHI; n=1,711).Findings: We identified an 84-metabolite signature of PHDI (Pearson r=0·46), characterised by higher long-chain highly unsaturated lipids and plant-related amino acids and lower carnitines and saturated lipid species, reflecting favourable lipid remodelling and oxidative stress modulation. Higher metabolomic PHDI was associated with lower risks of CVD (hazard ratio [HR] per 1-SD increment 0·95 [95% CI 0·90-1·00]) and total mortality (0·93 [0·89-0·96]), independently of self-reported PHDI, BMI, and other conventional risk factors. The signature was replicated in WHI for CVD (0·92 [0·84-1·00]).Interpretation: We identified and validated a metabolomic signature of PHDI that captures biological pathways linking adherence to a sustainable dietary pattern with cardiovascular health. These findings provide mechanistic insight into the potential cardiometabolic benefits of the planetary health diet and identify metabolic pathways that could inform future prevention strategies.
- 31 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (10) , 1770-1780
Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Background: Poor oral health, including periodontal disease and tooth loss, is linked to systemic inflammation and oral microbial dysbiosis, which may promote liver carcinogenesis through the oral–gut–liver axis. However, epidemiologic evidence on oral health and liver cancer risk remains inconsistent. We examined these associations in three prospective US cohorts and conducted a systematic review and meta-analysis of prospective studies. Methods: We pooled data from the Health Professionals Follow-Up Study, Nurses’ Health Study, and Women’s Health Initiative (230,915 participants, 198 liver cancer cases). Oral health, including periodontal disease and tooth loss, was self-reported. Multivariable-adjusted Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI). A systematic review through September 2025 identified four additional prospective studies, which were combined with pooled results in meta-analyses. Results: In the pooled analyses, periodontal disease (HR = 0.99; 95% CI, 0.67–1.47) and complete tooth loss (HR = 1.29; 95% CI, 0.71–2.35) were not associated with liver cancer risk. In the meta-analysis, dominated by one large study, periodontal disease was associated with an increased liver cancer risk (HR = 1.08; 95% CI, 1.03–1.13; n = 4 studies; I2 = 0%). In a linear dose–response meta-analysis, complete tooth loss was associated with an increased risk (HR = 1.32; 95% CI, 1.06–1.66; n = 6; I2 = 0%). Conclusions: The findings of the current investigation suggest that although an association between oral health and liver cancer is possible, the results remain inconclusive. Impact: These findings underscore the need for more studies using harmonized oral health assessments integrating clinical, microbial, and behavioral data to better capture the oral health burden.
- 31 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (10) , 1770-1780
Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses
Background: Poor oral health, including periodontal disease and tooth loss, is linked to systemic inflammation and oral microbial dysbiosis, which may promote liver carcinogenesis through the oral–gut–liver axis. However, epidemiologic evidence on oral health and liver cancer risk remains inconsistent. We examined these associations in three prospective US cohorts and conducted a systematic review and meta-analysis of prospective studies. Methods: We pooled data from the Health Professionals Follow-Up Study, Nurses’ Health Study, and Women’s Health Initiative (230,915 participants, 198 liver cancer cases). Oral health, including periodontal disease and tooth loss, was self-reported. Multivariable-adjusted Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI). A systematic review through September 2025 identified four additional prospective studies, which were combined with pooled results in meta-analyses. Results: In the pooled analyses, periodontal disease (HR = 0.99; 95% CI, 0.67–1.47) and complete tooth loss (HR = 1.29; 95% CI, 0.71–2.35) were not associated with liver cancer risk. In the meta-analysis, dominated by one large study, periodontal disease was associated with an increased liver cancer risk (HR = 1.08; 95% CI, 1.03–1.13; n = 4 studies; I2 = 0%). In a linear dose–response meta-analysis, complete tooth loss was associated with an increased risk (HR = 1.32; 95% CI, 1.06–1.66; n = 6; I2 = 0%). Conclusions: The findings of the current investigation suggest that although an association between oral health and liver cancer is possible, the results remain inconclusive. Impact: These findings underscore the need for more studies using harmonized oral health assessments integrating clinical, microbial, and behavioral data to better capture the oral health burden.
- Open Access
- 24 July 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (5)
Alcohol intake and risk of stomach cancer: a pooled analysis of 20 cohorts
Background: Stomach cancer presents complex etiological heterogeneity. Ethanol in alcoholic beverages and its metabolite acetaldehyde are carcinogens causally linked to several cancers, but their role in gastric carcinogenesis has not been established. We analyzed harmonized, individual-level prospective data to examine associations between alcohol intake and risk of stomach cancer and its subtypes. Methods: In total, 2 009 951 participants in 20 cohorts (mean follow-up = 9 to 29 years) within the Pooling Project of Prospective Studies of Diet and Cancer (n = 8357 incident invasive gastric adenocarcinomas) were included. We used Cox regression to assess associations between alcohol intake and risk of stomach cancer overall and by anatomical and histological subtype and population subgroup, adjusting for confounders. Results: Evidence for an association between alcohol intake and overall stomach cancer risk was weak (hazard ratio, HR, for ≥30 vs 0.1-<5 g/day: 1.06 [95% confidence interval, CI = 0.96 to 1.16], Pbetween-studies heterogeneity = .43). Positive associations with stomach cancer risk were observed in never smokers (HR, for ≥30 vs 0.1- .05). Conclusion: There was little evidence of an overall association between alcohol intake and stomach cancer risk, although modest positive associations were observed among never smokers and in Asian
- 24 July 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (5)
Open AccessAlcohol intake and risk of stomach cancer: a pooled analysis of 20 cohorts
Background: Stomach cancer presents complex etiological heterogeneity. Ethanol in alcoholic beverages and its metabolite acetaldehyde are carcinogens causally linked to several cancers, but their role in gastric carcinogenesis has not been established. We analyzed harmonized, individual-level prospective data to examine associations between alcohol intake and risk of stomach cancer and its subtypes. Methods: In total, 2 009 951 participants in 20 cohorts (mean follow-up = 9 to 29 years) within the Pooling Project of Prospective Studies of Diet and Cancer (n = 8357 incident invasive gastric adenocarcinomas) were included. We used Cox regression to assess associations between alcohol intake and risk of stomach cancer overall and by anatomical and histological subtype and population subgroup, adjusting for confounders. Results: Evidence for an association between alcohol intake and overall stomach cancer risk was weak (hazard ratio, HR, for ≥30 vs 0.1-<5 g/day: 1.06 [95% confidence interval, CI = 0.96 to 1.16], Pbetween-studies heterogeneity = .43). Positive associations with stomach cancer risk were observed in never smokers (HR, for ≥30 vs 0.1- .05). Conclusion: There was little evidence of an overall association between alcohol intake and stomach cancer risk, although modest positive associations were observed among never smokers and in Asian
- Open Access
- 7 July 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (1) , 16-27
Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials
BACKGROUND: During the 18-month CENTRAL (Effect of Weight-Loss Diet Strategies and Exercise on Dynamics of Body Fat Depots and Metabolic Rate) and DIRECT-PLUS (Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed) randomized controlled trials, participants achieved considerable reductions in abdominal and ectopic fat. We examined the long-term postintervention cardiometabolic profile associated with these changes. METHODS: We invited participants from CENTRAL (2012–2014) and DIRECT-PLUS (2017–2018), which evaluated dietary patterns (low-fat, healthy dietary guidelines and Mediterranean diet variants, including standard, low-carbohydrate, and polyphenol-enriched “green” Mediterranean diets) combined with structured physical activity. Participants underwent additional magnetic resonance imaging of visceral adipose tissue, deep subcutaneous adipose tissue (SAT), superficial SAT, intrahepatic fat, and intrapancreatic fat, along with clinical follow-up measurements, 5 and 10 years after completion of the trials. RESULTS: We reached 366 out of 381 eligible participants (96%) for follow-up. Despite complete weight regain, waist circumference and abdominal fat depots, including visceral adipose tissue, deep SAT, and superficial SAT, partially preserved their intervention-induced achievements at long-term follow-up (false discovery rate ≤0.01 for all). In contrast, postintervention reductions of intrahepatic fat and intrapancreatic fat were fully and excessively gained during follow-up, respectively (false discovery rate ≤0.01 for both). Each 10% intervention-induced loss of visceral adipose tissue, superficial SAT, and intrapancreatic fat were associated with long-term postintervention improvements in Metabolic Score for Insulin Resistance, composite risk score, and Metabolic Syndrome Severity Score (meta-analysis models adjusted to weight change, Mediterranean diet adherence and physical activity scores at follow-up, and further measures; all P <0.05). Only 10% visceral adipose tissue loss, however, was independently associated with a 28% lower risk of incident type 2 diabetes (hazard ratio, 0.72 [95% CI, 0.54–0.94]; multivariable model) during follow-up. CONCLUSIONS: This 5- and 10-year follow-up of 18-month clinical trials suggests that diet and physical activity lifestyle interventions may yield long-term improvements in cardiometabolic measures despite weight regain. A 10% reduction in visceral fat due to lifestyle interventions may reduce future type 2 diabetes risk by nearly 30%. Visceral fat loss rather than weight loss emerges as a key target for durable cardiometabolic health. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01530724 and NCT03020186.
- 7 July 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (1) , 16-27
Open AccessLifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials
BACKGROUND: During the 18-month CENTRAL (Effect of Weight-Loss Diet Strategies and Exercise on Dynamics of Body Fat Depots and Metabolic Rate) and DIRECT-PLUS (Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed) randomized controlled trials, participants achieved considerable reductions in abdominal and ectopic fat. We examined the long-term postintervention cardiometabolic profile associated with these changes. METHODS: We invited participants from CENTRAL (2012–2014) and DIRECT-PLUS (2017–2018), which evaluated dietary patterns (low-fat, healthy dietary guidelines and Mediterranean diet variants, including standard, low-carbohydrate, and polyphenol-enriched “green” Mediterranean diets) combined with structured physical activity. Participants underwent additional magnetic resonance imaging of visceral adipose tissue, deep subcutaneous adipose tissue (SAT), superficial SAT, intrahepatic fat, and intrapancreatic fat, along with clinical follow-up measurements, 5 and 10 years after completion of the trials. RESULTS: We reached 366 out of 381 eligible participants (96%) for follow-up. Despite complete weight regain, waist circumference and abdominal fat depots, including visceral adipose tissue, deep SAT, and superficial SAT, partially preserved their intervention-induced achievements at long-term follow-up (false discovery rate ≤0.01 for all). In contrast, postintervention reductions of intrahepatic fat and intrapancreatic fat were fully and excessively gained during follow-up, respectively (false discovery rate ≤0.01 for both). Each 10% intervention-induced loss of visceral adipose tissue, superficial SAT, and intrapancreatic fat were associated with long-term postintervention improvements in Metabolic Score for Insulin Resistance, composite risk score, and Metabolic Syndrome Severity Score (meta-analysis models adjusted to weight change, Mediterranean diet adherence and physical activity scores at follow-up, and further measures; all P <0.05). Only 10% visceral adipose tissue loss, however, was independently associated with a 28% lower risk of incident type 2 diabetes (hazard ratio, 0.72 [95% CI, 0.54–0.94]; multivariable model) during follow-up. CONCLUSIONS: This 5- and 10-year follow-up of 18-month clinical trials suggests that diet and physical activity lifestyle interventions may yield long-term improvements in cardiometabolic measures despite weight regain. A 10% reduction in visceral fat due to lifestyle interventions may reduce future type 2 diabetes risk by nearly 30%. Visceral fat loss rather than weight loss emerges as a key target for durable cardiometabolic health. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01530724 and NCT03020186.